Selected polymorphisms in sex hormone-related genes, circulating sex hormones and risk of endometrial cancer

Cancer Epidemiology

Volumn 36, Issue 5, 2012, Pages 445-452

  Lundin, Eva ^a   Wirgin, Isaac ^b   Lukanova, Annekatrin ^b,c   Afanasyeva, Yelena ^b   Krogh, Vittorio ^d   Axelsson, Tomas ^e   Hemminki, Kari ^c,f,g   Clendenen, Tess V ^b   Arslan, Alan A ^b   Ohlson, Nina ^a   Sieri, Sabina ^d   Roy, Nirmal ^b   Koenig, Karen L ^b   Idahl, Annika ^a   Berrino, Franco ^d   Toniolo, Paolo ^b,h   Hallmans, Göran ^a   Försti, Asta ^c,g   Muti, Paola ^i,j   Lenner, Per ^k   Shore, Roy E ^b,l   Zeleniuch Jacquotte, Anne ^b   more..

^a UMEÅ UNIVERSITY   (Sweden)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e UPPSALA UNIVERSITY   (Sweden)

^f KAROLINSKA INSTITUTE   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

ⁱ MCMASTER UNIVERSITY   (Canada)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^l RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

more..

Author keywords

Endometrial cancer; Estrogen; Progesterone receptor; Sex hormone binding globulin; Single nucleotide polymorphism

Indexed keywords

ESTRADIOL; ESTRONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN;

ADULT; ALLELE; ARTICLE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYP19 GENE; CYP1B1 GENE; ENDOMETRIUM CANCER; ESR1 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; PGR GENE; POSTMENOPAUSE; PRIORITY JOURNAL; SHBG GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UGT1A1 GENE;

AGED; AROMATASE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HUMANS; ITALY; MIDDLE AGED; NEW YORK CITY; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; RECEPTORS, PROGESTERONE; SEX HORMONE-BINDING GLOBULIN; SWEDEN;

EID: 84866238503     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.04.006     Document Type: Article

References (59)

1. Key T.J.A., Pike M.C. The dose-effect relationship between unopposed estrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988, 57:205-212.
2. Zeleniuch-Jacquotte A., Akhmedkhanov A., Kato I., Koenig K.L., Shore R.E., Kim M.Y., et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001, 84:975-981.
3. Lukanova A., Lundin E., Micheli A., Arslan A.A., Ferrari P., Rinaldi S., et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004, 108:425-432.
4. Allen N.E., Key T.J., Dossus L., Rinaldi S., Cust A., Lukanova A., et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Rel Cancer 2008, 15(2):485-497.
5. Olson S., Bandera E., Orlow I. Variants in estrogen biosynthesis genes, sex steroid hormone levels, and endometrial cancer: a HuGE review. Am J Epidemiol 2007, 165(3):235-245.
6. Yang H.P., Gonzalez Bosquet J., Li Q., Platz E.A., Brinton L.A., Sherman M.E., et al. Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. Carcinogenesis 2010, 31(5):827-833.
7. Paynter R.A., Hankinson S.E., Colditz G.A., Kraft P., Hunter D.J., De Vivo I., et al. CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer 2005, 116(2):267-274. [Erratum appears in Int J Cancer 1975;37(2):635-47 2008;122(15 March (6)):1443].
8. Haiman C., Dossus L., Setiawan V., Stram D., Dunning A., Thomas G., et al. Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 2007, 67(5):1893-1897.
9. Dunning A.M., Dowsett M., Healey C.S., Tee L., Luben R.N., Folkerd E., et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004, 96(12):936-945.
10. Cui Y., Shu X.O., Cai Q., Jin F., Cheng J.R., Cai H., et al. Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1096-1101.
11. Ding E., Song Y., Manson J., Hunter D., Lee C., Rifai N., et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009, 361(12):1152-1163.
12. Guillemette C., De Vivo I., Hankinson S.E., Haiman C.A., Spiegelman D., Housman D.E., et al. Association of genetic polymorphisms in UGT1A1 and breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001, 10:711-714.
13. De Vivo I., Hankinson S.E., Li L., Colditz G.A., Hunter D.J. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:489-492.
14. Romano A., Delvoux B., Fischer D.-C., Groothuis P. The PROGINS polymorphism of the human progesterone receptor diminishes the response to progesterone. J Mol Endocrinol 2007, 38(1-2):331-350.
15. Herrington D.M., Howard T.D., Brosnihan K.B., McDonnell D.P., Li X., Hawkins G.A., et al. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002, 105(16):1879-1882.
16. Junqueira M.G., da Silva I.D., Nogueira-de-Souza N.C., Carvalho C.V., Leite D.B., Gomes M.T., et al. Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development. Int J Gastrointest Cancer 2007, 17(1):229-232.
17. Duguay Y., McGrath M., Lepine J., Gagne J.F., Hankinson S.E., Colditz G.A., et al. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res 2004, 64(3):1202-1207.
18. Kataoka N., Cai Q., Xu W.H., Xiang Y.B., Cai H., Zheng W., et al. Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene. Cancer 2007, 109(7):1296-1302.
19. McGrath M., Hankinson S.E., Arbeitman L., Colditz G.A., Hunter D.J., De Vivo I., et al. Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 2004, 25(4):559-565.
20. Sasaki M., Tanaka Y., Kaneuchi M., Sakuragi N., Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor a and estrogen receptor b expressions. Cancer Res 2003, 63:3913-3918.
21. Wedren S., Lovmar L., Humphreys K., Magnusson C., Melhus H., Syvanen A.C., et al. Estrogen receptor alpha gene polymorphism and endometrial cancer risk-a case-control study. BMC Cancer 2008, 8:322.
22. Shimada T., Watanabe J., Kawajiri K., Sutter T.R., Guengerich F.P., Gillam E.M.J., et al. Catalytic properties of human polymorphic P 450 1B1 variants. Carcinogenesis 1999, 20:1607-1613.
23. McGrath M., Lépine J., Lee I.M., Villeneuve L., Buring J., Guillemette C., et al. Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet Genomics 2009, 19(3):239-243.
24. Thompson D.J., Healey C.S., Baynes C., Kalmyrzaev B., Ahmed S., Dowsett M., et al. Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3490-3498.
25. Lee E., Hsu C., Haiman C., Razavi P., Horn-Ross P., Van Den Berg D., et al. Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach. Carcinogenesis 2010, 31(8):1392-1399.
26. De Vivo I., Huggins G.S., Hankinson S.E., Lescault P.J., Boezen M., Colditz G.A., et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 2002, 99:12263-12268.
27. Xu W.H., Long J.R., Zheng W., Ruan Z.X., Cai Q., Cheng J.R., et al. Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population. Cancer 2009, 115(12):2693-2700.
28. Weiderpass E., Persson I., Melhus H., Wedren S., Kindmark A., Baron J.A. Estrogen receptor a gene polymorphisms and endometrial cancer risk. Carcinogenesis 2000, 21:623-627.
29. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al. Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 2009, 116(8):1053-1061.
30. Zeleniuch-Jacquotte A., Shore R.E., Koenig K.L., Akhmedkhanov A., Afanasyeva Y., Kato I., et al. Postmenopausal levels of estrogen, androgen, and SHBG and breast cancer risk: long-term results of a prospective study. Br J Cancer 2004, 90:153-159.
31. Hulten K., Van Kappel A.L., Winkvist A., Kaaks R., Hallmans G., Lenner P., et al. Carotenoids, alpha-tocopherols, and retinol in plasma and breast cancer risk in northern Sweden. Cancer Causes Control 2001, 12(6):529-537.
32. Toniolo P., Levitz M., Zeleniuch-Jacquotte A., Banerjee S., Koenig K.L., Shore R.E., et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995, 87:190-197.
33. Muti P., Bradlow H.L., Micheli A., Krogh V., Freudenheim J.L., Schunemann H.J., et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 2000, 11:635-640.
34. Hui L., DelMonte T., Ranade K. Genotyping using the TaqMan assay. Curr Protoc Hum Genet 2008, [chapter 2: unit 2.10].
35. Shen G., Luo A., Wang Q. High-throughput single-nucleotide polymorphisms genotyping: TaqMan assay and pyrosequencing assay. Methods Mol Med 2006, 128:209-224.
36. Rinaldi S., Geay A., Dãâ©chaud H., Biessy C., Zeleniuch-Jacquotte A., Akhmedkhanov A., et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002, 11:1065-1071.
37. Deming S.L., Zheng W., Xu W.H., Cai Q., Ruan Z., Xiang Y.B., et al. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2008, 17(3):563-570.
38. Setiawan V.W., Doherty J.A., Shu X.O., Akbari M.R., Chen C., De Vivo I., et al. Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18(1):242-247.
39. Low Y.L., Li Y., Humphreys K., Thalamuthu A., Darabi H., Wedren S., et al. Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility. PLoS Genet 2010, 6:e1001012.
40. Beckmann L., Husing A., Setiawan V.W., Amiano P., Clavel-Chapelon F., Chanock S.J., et al. Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab 2011, 96(2):E360-E367.
41. Clarke C.L., Sutherland R.L. Progestin regulation of cellular proliferation. Endocr Rev 1990, 11(2):266-301.
42. Gellersen B., Brosens J. Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. J Endocrinol 2003, 178(3):357-372.
43. O'Mara T.A., Fahey P., Ferguson K., Marquart L., Lambrechts D., Despierre E., et al. Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis 2011, 32(3):331-335.
44. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al. Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol 2010, 34(3):328-337.
45. Pearce C.L., Wu A.H., Gayther S.A., Bale A.E., Beck P.A., Beesley J., et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer 2008, 98(2):282-288.
46. Riancho J.A., Valero C., Zarrabeitia M.T., Garcia-Unzueta M.T., Amado J.A., Gonzalez-Macias J. Genetic polymorphisms are associated with serum levels of sex hormone binding globulin in postmenopausal women. BMC Med Genet 2008, 9:112.
47. Haiman C., Riley S., Freedman M., Setiawan V., Conti D., Le Marchand L. Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab 2005, 90(4):2198-2204.
48. Napoli N., Varadharajan A., Rini G.B., Del Fiacco R., Yarramaneni J., Mumm S., et al. Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density. Bone 2009, 45(6):1169-1174.
49. Cousin P., Dechaud H., Grenot C., Lejeune H., Pugeat M. Human variant sex hormone-binding globulin (SHBG) with an additional carbohydrate chain has a reduced clearance rate in rabbit. J Clin Endocrinol Metab 1998, 83(1):235-240.
50. Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N., et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999, 22(3):231-238.
51. Rebbeck T.R., Troxel A.B., Wang Y., Walker A.H., Panossian S., Gallagher S., et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst 2006, 98(18):1311-1320.
52. Sparks R., Ulrich C.M., Bigler J., Tworoger S.S., Yasui Y., Rajan K.B., et al. UDP-glucuronyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 2004, 6:R488-R498.
53. Rylander-Rudqvist T., Wedren S., Jonasdottir G., Ahlberg S., Weiderpass E., Persson I., et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2004, 13(9):1515-1520.
54. Doherty J.A., Weiss N.S., Dightman D., Houck J., Chen C. Polymorphisms in CYP1A1, CYP1A2, CYP1B1, and COMT and risk of endometrial cancer. Proc Am Assoc Cancer Res 2001, 42:2687.
55. Tao M.H., Cai Q., Xu W.H., Kataoka N., Wen W., Zheng W., et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2006, 15(12):2570-2573.
56. Sliwinski T., Sitarek P., Stetkiewicz T., Sobczuk A., Blasiak J. Polymorphism of the ERalpha and CYP1B1 genes in endometrial cancer in a Polish subpopulation. J Obstet Gynaecol Res 2010, 36(2):311-317.
57. Wang F., Zou Y.F., Sun G.P., Su H., Huang F. Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: a meta-analysis. Eur J Cancer Prev 2011, 20(2):112-120.
58. Tworoger S., Chubak J., Aiello E., Ulrich C., Atkinson C., Potter J., et al. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004, 13(1):94-101.
59. Dunning A.M., Healey C.S., Baynes C., Maia A.T., Scollen S., Vega A., et al. Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009, 18(6):1131-1139.